While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...

The advent of chimeric antigen receptor (CAR)-T cell therapy has marked the onset of a very promising option to treat solid tumors after its remarkable ...

During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell ...

An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...

Potent CAR-T expansion from a single, off-the-shelf infusion without chemotherapy ...

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high response rates and minimal long-term toxicity.

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...

Lisocabtagene maraleucel (liso-cel) is now the only CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for MZL. The approval marks liso-cel’s fifth indication, the most of any ...

The CAR T-cell therapy market offers significant growth opportunities driven by technological advancements, personalized ...

Please provide your email address to receive an email when new articles are posted on . CAR T-cell therapy for cancer may be associated with new-onset autoimmune disease. Autoimmune events in after ...